Richard Gaynor
Richard Gaynor's purchase track record
Richard Gaynor has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 7/1/2026 | ZLAB | $33K | +37.5% | pending | — |
| 3/17/2026 | ZLAB | $33K | -6.8% | +30.4% | +13.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Baird Highlights Growth Potential for Alkermes plc (ALKS). Baird has highlighted Alkermes plc as a company with promising growth potential, citing its pipeline and recent developments. A Yahoo article compares Alkermes to LQDA, discussing which biotech may be more attractive for investors. The stock is currently trading near its 200‑day moving average and close to a key support level of $48.74, while analysts average a target of $56.56.
Transaction History
| ZLAB | ▲ Buy | Open Market | 1,736 | $33K | 7/1/2026 | View on chart |
| ZLAB | ▲ Buy | Grant | 22,371 | $0 | 6/17/2026 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 6,142 | — | 5/21/2026 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 1,475 | $55K | 5/21/2026 | View on chart |
| ZLAB | ▲ Buy | Open Market | 1,731 | $33K | 3/17/2026 | View on chart |
| ZLAB | ▲ Buy | Grant | 10,831 | $0 | 6/18/2025 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 8,013 | — | 5/31/2025 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 1,924 | $59K | 5/31/2025 | View on chart |
| ZLAB | ▼ Sell | Open Market | 2,500 | $88K | 3/5/2025 | View on chart |
| ZLAB | ▼ Sell | Open Market | 2,500 | $49K | 9/3/2024 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 1,465 | $35K | 6/29/2024 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 6,104 | — | 6/29/2024 | View on chart |
| ZLAB | ▲ Buy | Grant | 21,253 | $0 | 6/18/2024 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 1,430 | $43K | 7/7/2023 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 5,957 | — | 7/7/2023 | View on chart |
| ZLAB | ▲ Buy | Grant | 18,903 | $500K | 6/29/2023 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 7,585 | — | 6/14/2022 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 695 | $19K | 6/14/2022 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 5,578 | — | 12/2/2021 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 1,339 | $30K | 12/2/2021 | View on chart |
| ZLAB | ▲ Buy | Grant | 8,912 | $0 | 11/19/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Zai Lab Releases Q2 2026 Earnings and Call Transcript
Zai Lab has published its second-quarter 2026 financial results along with the full earnings call transcript. This update provides investors with the latest details on the company's performance and strategic outlook. The stock is currently trading within its 52-week range, with analysts maintaining a wide target price spread.
Zai Lab Releases Q2 2026 Earnings and Call Transcript. Zai Lab has published its second-quarter 2026 financial results along with the full earnings call transcript. This update provides investors with the latest details on the company's performance and strategic outlook. The stock is currently trading within its 52-week range, with analysts maintaining a wide target price spread.